Pfizer ($PFE) has agreed to sell 260 million doses of its pneumococcal vaccine Prevnar 13 at a small fraction of their usual price to open access to the shots to people in poor countries. Report
Pfizer ($PFE) has agreed to sell 260 million doses of its pneumococcal vaccine Prevnar 13 at a small fraction of their usual price to open access to the shots to people in poor countries. Report